Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis-Reference-Cited by-同舟云学术

Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis

Published:2022-02-27 Issue:1 Volume:27 Page:300-309
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Li Jun¹²,Yin Xiaoping¹

Affiliation:

1. Taixing People’s Hospital, Taixing, People’s Republic of China

2. School of Medicine, Southeast University, Nanjing, People’s Republic of China

Funder

Key Medical of Jiangsu Province

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2022.2042964

Reference50 articles.

1. Acute Myeloid Leukemia

2. Henderson E. Treatment of acute leukemia. in Seminars Hematol, 6: 271–319 (July 1969). 1969. National Cancer Inst., Bethesda, Md.

3. Acute Myeloid Leukemia

4. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

5. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

2. Antibody–drug conjugate: Emerging trend for targeted treatment;Polymer-Drug Conjugates;2023

3. Antibody-Drug Conjugates in Myeloid Leukemias;The Cancer Journal;2022-11